Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bolli

Showing results (1201-1210 of 1,218) with videos related to

Pageof 122
Sort By:
Nature Medicine|March 25, 2026
Enhanced dynamic risk stratification of smoldering multiple myelomaFloris Chabrun, Daniel E Schwartz, Susanna Gentile, et al.
Elife|October 2, 2014
Origins and functional consequences of somatic mitochondrial DNA mutations in human cancerYoung Seok Ju, Ludmil B Alexandrov, Moritz Gerstung, et al.
Nature Genetics|February 7, 2020
Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotranspositionBernardo Rodriguez-Martin, Eva G Alvarez, Adrian Baez-Ortega, et al.
Circulation|February 18, 2017
Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells)Emerson C Perin, Michael P Murphy, Keith L March, et al.
Haematologica|March 6, 2025
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world dataEnrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.
European Journal of Haematology|March 19, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 PatientsFortunato Morabito, Enrica Antonia Martino, Monica Galli, et al.
The Canadian Journal of Cardiology|August 2, 2011
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapyDoreen M Rabi, Stella S Daskalopoulou, Raj S Padwal, et al.
The Canadian Journal of Cardiology|May 19, 2012
The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapyStella S Daskalopoulou, Nadia A Khan, Robert R Quinn, et al.
The Canadian Journal of Cardiology|April 2, 2013
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertensionDaniel G Hackam, Robert R Quinn, Pietro Ravani, et al.
The Canadian Journal of Cardiology|May 5, 2015
The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertensionStella S Daskalopoulou, Doreen M Rabi, Kelly B Zarnke, et al.
Pageof 122

Showing results (1201-1210 of 1,218) with videos related to

Sort By:
Pageof 122
Nature Medicine|March 25, 2026
Enhanced dynamic risk stratification of smoldering multiple myelomaFloris Chabrun, Daniel E Schwartz, Susanna Gentile, et al.
Elife|October 2, 2014
Origins and functional consequences of somatic mitochondrial DNA mutations in human cancerYoung Seok Ju, Ludmil B Alexandrov, Moritz Gerstung, et al.
Nature Genetics|February 7, 2020
Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotranspositionBernardo Rodriguez-Martin, Eva G Alvarez, Adrian Baez-Ortega, et al.
Circulation|February 18, 2017
Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells)Emerson C Perin, Michael P Murphy, Keith L March, et al.
Haematologica|March 6, 2025
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world dataEnrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.
European Journal of Haematology|March 19, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 PatientsFortunato Morabito, Enrica Antonia Martino, Monica Galli, et al.
The Canadian Journal of Cardiology|August 2, 2011
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapyDoreen M Rabi, Stella S Daskalopoulou, Raj S Padwal, et al.
The Canadian Journal of Cardiology|May 19, 2012
The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapyStella S Daskalopoulou, Nadia A Khan, Robert R Quinn, et al.
The Canadian Journal of Cardiology|April 2, 2013
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertensionDaniel G Hackam, Robert R Quinn, Pietro Ravani, et al.
The Canadian Journal of Cardiology|May 5, 2015
The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertensionStella S Daskalopoulou, Doreen M Rabi, Kelly B Zarnke, et al.
Pageof 122